GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Disc Medicine Inc.
Shares of Disc Medicine, a biotech company focused on treating rare blood diseases, are driven by news from clinical trials. The price chart reflects investor confidence in the potential of its hematological research.
Share prices of companies in the market segment - Cancer blood
Disc Medicine is a biotech company specializing in the treatment of rare blood diseases. We classify it in the Cancer Blood sector, and the chart below shows the overall performance of biotech companies, where valuation is determined by clinical trial results.
Broad Market Index - GURU.Markets
Disc Medicine is a biopharmaceutical company developing drugs for the treatment of rare hematological diseases. Its focus on this niche makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Disc Medicine compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
IRON - Daily change in the company's share price Disc Medicine Inc.
Shares of Disc Medicine, a company focused on treating rare blood diseases, are highly volatile. change_co tracks investor reactions to clinical trial news. This seemingly simple parameter forms the basis for advanced biotech risk analysis formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Cancer blood
Disc Medicine, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with IRON, which focuses on blood disorders, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Disc Medicine is a biopharmaceutical company specializing in the treatment of hematological diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Disc Medicine's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Disc Medicine Inc.
Disc Medicine is a biotech company developing cell therapy for blood cancer. Its shares are a bet on a breakthrough in medicine. Their high volatility, driven by research results, contributes to the dynamics of the entire innovative market sector.
Annual dynamics of market capitalization of the market segment - Cancer blood
Disc Medicine, Inc. is a clinical-stage biotech company focused on treating rare blood diseases. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Disc Medicine is a clinical-stage biotech whose value reflects the hopes of developing new drugs. Its shares exhibit extreme volatility and are completely disconnected from economic cycles. The company's chart isn't about business, but about binary events: the success or failure of clinical trials.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Disc Medicine Inc.
Disc Medicine, a biotech company specializing in the treatment of rare blood diseases. The sharp monthly fluctuations on the chart reflect the publication of clinical trial data, a key factor for companies at this stage.
Monthly dynamics of market capitalization of the market segment - Cancer blood
The biotech sector, focused on rare blood diseases, is valued by investors based on the potential of its scientific developments. The market capitalization dynamics of this niche, reflected in the chart, reveal high volatility and dependence on clinical trial data. This is the context for companies like Disc Medicine.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Disc Medicine is a biotech company focused on treating rare blood diseases. Its stock moves based on clinical trial results. Their performance is completely disconnected from overall market trends and is a pure bet on scientific success.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Disc Medicine Inc.
Disc Medicine is a clinical-stage biopharmaceutical company focused on treating rare blood diseases. Its weekly stock price, like that of other biotech companies, is entirely dependent on news about the progress of clinical trials. Positive data can trigger a dramatic increase in its stock price.
Weekly dynamics of market capitalization of the market segment - Cancer blood
Disc Medicine, as a clinical-stage biotech, exists in its own universe. Its weekly performance is 100% dependent on clinical trial news, not on general pharmaceutical industry trends. The chart clearly demonstrates these sharp, sector-neutral ups and downs, typical of biotechs on the cusp of breakthroughs.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Disc Medicine is a biotech company specializing in the treatment of blood diseases. Its shares are driven by news of clinical trials. The chart clearly shows how much its performance is detached from the market and driven by scientific data.
Market capitalization of the company, segment and market as a whole
IRON - Market capitalization of the company Disc Medicine Inc.
Disc Medicine's market capitalization chart represents the biotech company's focus on treating rare blood diseases. Its valuation, like many companies in this sector, is entirely dependent on progress in clinical trials. Sharp movements on the chart are a direct reaction from investors to the release of efficacy and safety data for its drug candidates.
IRON - Share of the company's market capitalization Disc Medicine Inc. within the market segment - Cancer blood
Disc Medicine is a biotech company seeking to capture market share in rare blood disorders. Its market capitalization is based on the potential of its drugs, which target new mechanisms of hemoglobin regulation and iron metabolism.
Market capitalization of the market segment - Cancer blood
The chart below shows the overall value of the biotech sector, and Disc Medicine is an interesting player focused on treating hematological diseases. The company is developing new approaches to treating iron metabolism disorders. This market has significant potential, and Disc Medicine is seeking to carve out its niche in it.
Market capitalization of all companies included in a broad market index - GURU.Markets
Disc Medicine develops drugs to treat rare blood diseases. Its market capitalization is based on the hope of creating new therapies for patients with limited treatment options. The chart below shows the weight of biotech companies operating in narrow but important niches.
Book value capitalization of the company, segment and market as a whole
IRON - Book value capitalization of the company Disc Medicine Inc.
Disc Medicine's book value represents capital raised to develop new treatments for rare hematological diseases. The company's foundation is its scientific platform and clinical trial data. The graph is the financial benchmark for a biotech company whose mission is to transform science into tangible value through the creation of new drugs.
IRON - Share of the company's book capitalization Disc Medicine Inc. within the market segment - Cancer blood
Disc Medicine treats blood disorders. The chart shows its share of actual R&D assets. These are its laboratories where new therapeutic approaches are developed that could change the lives of patients with rare hematological disorders.
Market segment balance sheet capitalization - Cancer blood
Disc Medicine, Inc. is a clinical-stage biotechnology company, which accounts for its low capital intensity. Its value lies in the development of drugs for the treatment of hematological diseases, not in its manufacturing capacity. Compared to the pharmaceutical sector, its "light" balance sheet is typical of innovative R&D companies.
Book value of all companies included in the broad market index - GURU.Markets
Disc Medicine's assets are focused on the scientific discovery of new treatments for rare blood diseases. The company's balance sheet reflects the value of its clinical programs and intellectual property. The chart shows the volume of resources devoted to solving complex hematological problems that have previously lacked effective treatment.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Disc Medicine Inc.
Disc Medicine is a biotech company focused on treating rare blood diseases. Its market value is almost entirely derived from investor expectations regarding the success of its clinical programs. Its book value is minimal. The chart is essentially an indicator of the market's faith in its scientific approach and future drugs.
Market to book capitalization ratio in a market segment - Cancer blood
Disc Medicine is a biotech company focused on blood diseases. Its market valuation is entirely dependent on the prospects of its clinical developments. This chart shows the vast gap between its market cap based on hope and the trough valuation of its tangible assets, typical for this sector.
Market to book capitalization ratio for the market as a whole
Disc Medicine is a biotech company specializing in the treatment of blood diseases. Its market capitalization reflects investor expectations for clinical trial results. The chart below illustrates how, in biotech, market value can be tens of times higher than book value in anticipation of a breakthrough.
Debts of the company, segment and market as a whole
IRON - Company debts Disc Medicine Inc.
Disc Medicine is a biopharmaceutical company focused on treating rare blood diseases. Its research requires significant and long-term funding. Raising capital, including debt, allows the company to advance its innovative therapeutic approaches through the complex and costly stages of clinical development.
Market segment debts - Cancer blood
Disc Medicine is a clinical-stage biopharmaceutical company specializing in the treatment of hematological diseases. Funding in this sector is almost always through equity. This chart shows whether the company adheres to this standard model or uses other financial instruments to advance its drugs through clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Disc Medicine Inc.
Disc Medicine is a clinical-stage biotech company specializing in the treatment of hematological diseases. This chart shows a typical financial structure for the industry. The absence of debt and reliance on equity are essential for funding the costly and lengthy clinical trials of its experimental drugs.
Market segment debt to market segment book capitalization - Cancer blood
Disc Medicine is a biopharmaceutical company focused on treating rare blood diseases. This chart illustrates the overall debt burden in the hematology development sector. It provides insight into how the company's financial model for raising capital for clinical trials compares to accepted practices in this highly specialized niche.
Debt to book value of all companies in the market
Disc Medicine is a biotech company dependent on venture capital. The chart illustrates the overall debt burden across the economy. It highlights the worldview difference: while the overall market is preoccupied with interest rates, for Disc Medicine, the key is successfully completing clinical trials to attract the next round of investment.
P/E of the company, segment and market as a whole
P/E - Disc Medicine Inc.
For Disc Medicine, a biotech company focused on blood disorders, this chart represents a buy into a future breakthrough. While drugs are in development, the price-to-earnings ratio is relative. Investors evaluate the scientific platform and the potential of its drug candidates, not current revenue. The chart's dynamics reflect the company's reaction to clinical trial data.
P/E of the market segment - Cancer blood
This chart reflects the average valuation for the speculative biotech sector—a benchmark for Disc Medicine. The entire sector is valued based on expectations for future drugs. For investors, this benchmark reflects the overall level of optimism. Against this backdrop, one can gauge expectations for Disc Medicine's developments in the treatment of blood disorders.
P/E of the market as a whole
Disc Medicine is a biotech company focused on treating rare blood diseases. Its value depends almost entirely on the success of clinical trials. Investor sentiment, as shown in this chart, determines the availability of capital for such companies. During periods of market optimism, they easily raise funds, but during downturns, funding can become a challenge.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Disc Medicine Inc.
Disc Medicine is a biopharmaceutical company specializing in the treatment of rare blood diseases. Its value is almost entirely dependent on the success of its clinical trials. This chart reflects analysts' expectations regarding the potential of its drugs to become a new standard of care, which shapes forecasts for future, yet unearned, profits.
%20P%2FE%20Disc%20Medicine%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Disc-Medicine-Inc.&v=1772513928192 "Chart of the company's future (projected) P/E Disc Medicine Inc.")
Future (projected) P/E of the market segment - Cancer blood
Disc Medicine is a clinical-stage biopharmaceutical company specializing in the treatment of rare blood diseases. Its valuation relative to other biotechs reflects investor expectations for its innovative approach to hematology, demonstrating the market's confidence in the potential of its drugs to address unmet medical needs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772513928234 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
Disc Medicine is a biopharmaceutical company focused on treating rare blood diseases. Its value is determined almost entirely by expectations for clinical trials. This chart shows investors' overall risk appetite. For early-stage biotechs like Disc, market optimism is critical to raising the capital needed to continue development.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513928259 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Disc Medicine Inc.
Disc Medicine is a biopharmaceutical company specializing in the treatment of hematological diseases. Its financial indicators, presented in the chart, reflect progress in clinical development. Positive trial data and the potential of its drugs for the treatment of rare blood diseases underpin its current performance.
Profit of companies in the market segment - Cancer blood
Disc Medicine is a biotech company specializing in the treatment of rare blood diseases. This chart shows the aggregate profitability of companies operating in hematology. It helps understand whether this complex area of pharmaceuticals is commercially viable or a high-risk area requiring massive R&D investments.
Overall market profit
Disc Medicine is a biopharmaceutical company specializing in the treatment of rare blood diseases. Its trajectory is entirely dependent on the success of its drug development and clinical trials. This chart, which depicts general economic cycles, is of secondary importance to IRON compared to scientific data and regulatory decisions.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Disc Medicine Inc.
Disc Medicine is a biotech company specializing in the treatment of rare blood diseases. Like many companies at this stage, its future profitability depends entirely on the results of clinical trials. This chart reflects analyst consensus on the likelihood of success of its experimental drugs and their potential commercial impact.
%20profit%20of%20the%20company%20Disc%20Medicine%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Disc-Medicine-Inc.&v=1772513928328 "Graph of future (projected) profit of the company Disc Medicine Inc.")
Future (predicted) profit of companies in the market segment - Cancer blood
Disc Medicine is a biotech company focused on treating rare blood diseases. Their developments are aimed at modulating iron metabolism pathways in the body. This chart shows forecasts for the hematology pharmaceutical segment. It provides investors with context for assessing Disc Medicine's potential if its innovative approaches to treating complex diseases are successful.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772513928354 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
Disc Medicine, Inc. is a biopharmaceutical company specializing in the treatment of rare blood diseases. The overall economic backdrop, as shown by this chart, influences investor sentiment. Positive market expectations facilitate raising funds for expensive clinical trials, which are necessary for the development of innovative treatments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513928387 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Disc Medicine Inc.
Disc Medicine is a biotech company focused on treating rare blood diseases. With no commercial revenue, its valuation, as shown in this chart, is based entirely on expectations. Investors are betting on the success of clinical trials and future demand for its drugs.
P/S market segment - Cancer blood
Disc Medicine is a biopharmaceutical company focused on treating rare blood diseases. This chart shows the average valuation in the oncology and hematology sector. It reflects investor expectations for companies developing new approaches to treating serious hematological disorders and the potential for their drugs to become standard treatments.
P/S of the market as a whole
Disc Medicine, Inc. is a biopharmaceutical company focused on treating rare blood diseases. Its financial outlook is tied to the successful development and commercialization of its drug candidates. This chart provides a common frame of reference, allowing investors to evaluate expectations for the biotech company compared to established revenue-generating companies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Disc Medicine Inc.
Disc Medicine is a biopharmaceutical company specializing in the treatment of hematological diseases. Its valuation depends on the future success of clinical trials and the commercialization of its drug candidates. This chart reflects investors' confidence in the company's scientific platform and its potential to develop new treatments for blood diseases.
%20P%2FS%20Disc%20Medicine%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Disc-Medicine-Inc.&v=1772513928499 "The graph of the company's future (projected) P/S Disc Medicine Inc.")
Future (projected) P/S of the market segment - Cancer blood
Disc Medicine is a biopharmaceutical company focused on treating rare hematological diseases associated with iron metabolism disorders. Its developments have the potential to transform approaches to treating these conditions. This chart reflects investor expectations for the commercial potential of its niche drugs compared to other companies in the sector.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772513928546 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
This indicator shows the overall level of investor optimism in biotech. For Disc Medicine, which develops drugs to treat rare blood disorders, it's an indicator of capital availability. Market confidence in future breakthroughs allows the company to raise funds for clinical trials aimed at developing new treatments for patients with hematological disorders.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513928588 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Disc Medicine Inc.
Disc Medicine is a biopharmaceutical company focused on developing new treatments for serious hematological diseases. This chart reflects revenue from collaborations and development funding. In the future, as approvals are secured, it will reflect revenue from sales of drugs targeting iron metabolism and red blood cell formation.
Sales of companies in the market segment - Cancer blood
Disc Medicine is a biopharmaceutical company focused on treating rare blood disorders. This chart shows the market size of hematology drugs. Disc Medicine's innovative approaches target fundamental problems in iron metabolism, potentially leading to new treatment standards for patients with serious hematological disorders.
Overall market sales
Disc Medicine, Inc. is a biopharmaceutical company focused on treating rare blood diseases. Its value and prospects depend on the results of clinical trials. The overall economic environment, shown in this chart, influences investors' risk appetite and their willingness to fund long-term research and development in the biotech sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Disc Medicine Inc.
Disc Medicine is a biopharmaceutical company specializing in the treatment of rare blood disorders. Its developments are aimed at modulating iron metabolism pathways in the body. The company's future success depends on the results of clinical trials. This chart reflects analysts' confidence in Disc Medicine's scientific approach and the commercial potential of its drugs for the treatment of hematological disorders.
%20sales%20of%20the%20company%20Disc%20Medicine%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Disc-Medicine-Inc.&v=1772513928702 "Schedule of future (projected) sales of the company Disc Medicine Inc.")
Future (projected) sales of companies in the market segment - Cancer blood
Disc Medicine is a biopharmaceutical company focused on treating rare blood diseases. This forecast reflects expectations for the hematological oncology segment. It highlights the growth potential analysts see in developing new treatments for patients with limited therapeutic options, which is Disc Medicine's mission.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772513928744 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
Disc Medicine, Inc. is a biopharmaceutical company specializing in the treatment of serious hematological diseases. Its prospects depend on the success of clinical trials and the launch of its drugs. The overall economic situation, reflected in this chart, influences the level of funding in the biotech sector, which affects the company's ability to pursue its development.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513928764 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Disc Medicine Inc.
Disc Medicine is a biotech company focused on treating rare blood diseases. This chart reflects its research-intensive stage of development. Negative values represent investments in clinical trials of new drugs. Future profitability depends entirely on the success of these trials and subsequent regulatory approvals.
Market segment marginality - Cancer blood
Disc Medicine is a biopharmaceutical company specializing in the treatment of hematological diseases. Its financial metrics reflect its focus on clinical research. This chart provides insight into Disc's operational structure and level of R&D investment compared to other biotech companies operating in this field.
Market marginality as a whole
Disc Medicine is a biopharmaceutical company specializing in the treatment of hematological diseases. This total market margin chart is irrelevant to the company. The company's potential lies in developing new treatments for rare blood diseases. Its success will be measured by clinical outcomes and the ability to address unmet medical needs.
Employees in the company, segment and market as a whole
Number of employees in the company Disc Medicine Inc.
Disc Medicine is a biopharmaceutical company focused on treating rare hematological diseases. This chart shows the growing team of scientists and physicians advancing new treatments through clinical trials. Their number is an indicator of progress and investment in R&D.
Share of the company's employees Disc Medicine Inc. within the market segment - Cancer blood
Disc Medicine is focused on treating rare hematological diseases. In this narrow and complex field, its team of scientists is its greatest asset. This metric reflects the percentage of leading hematologists and biologists working on new approaches to treating blood diseases that the company attracts. It demonstrates its concentration of unique scientific expertise in solving rare medical problems.
Number of employees in the market segment - Cancer blood
Disc Medicine, Inc. is a biopharmaceutical company developing novel treatments for serious hematological diseases. It focuses on modulating iron and heme metabolism pathways. This chart depicts employment in the blood disorders sector, showing how scientific discoveries in hematology are leading to the creation of new therapeutic approaches and specialized jobs.
Number of employees in the market as a whole
Disc Medicine is a biopharmaceutical company specializing in the treatment of hematological diseases. Their work requires significant investment in research and highly qualified personnel. This is an example of how the innovation-driven healthcare sector creates jobs whose value is measured not by quantity but by intellectual contribution.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Disc Medicine Inc. (IRON)
Disc Medicine is a biopharmaceutical company focused on treating rare blood diseases. This chart is an example of valuing a promising research company. The very high market capitalization per employee suggests that the market is pricing in the potential success of their drugs in clinical trials. The value here represents the hope generated by a small team of scientists.
%20of%20the%20company%20Disc%20Medicine%20Inc.%20(IRON)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Disc-Medicine-Inc.-IRON&v=1772513929066 "Chart of market capitalization per employee (in thousands of dollars) of the company Disc Medicine Inc. (IRON)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
Disc Medicine (IRON) is a clinical-stage biopharmaceutical company specializing in the treatment of hematological (blood) diseases associated with iron metabolism disorders. This chart shows the industry average cost per employee. It helps assess how the market values their focused R&D portfolio and scientific team per employee.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772513929106 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
Disc Medicine is a biopharmaceutical company focused on treating serious hematological diseases. This chart shows the market average employee contribution, illustrating the company's high valuation of its scientific potential and developments in the field of rare diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513929131 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Disc Medicine Inc. (IRON)
Disc Medicine is a biotech company specializing in the treatment of blood diseases. Like most R&D companies without a commercial product, this chart shows the company's per-employee loss. It reflects how much the company spends on each scientist and physician during the development and clinical trials of new drugs.
%20Chart%20Disc%20Medicine%20Inc.%20(IRON)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Disc-Medicine-Inc.-IRON&v=1772513929180 "Company Profit Per Employee (in thousands of dollars) Chart Disc Medicine Inc. (IRON)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
Disc Medicine (IRON) is an R&D biotech (blood diseases). This chart shows the benchmark for "Cancer/Blood Treatment" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772513929194 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
Disc Medicine is a clinical-stage biopharmaceutical company specializing in the treatment of hematological (blood) diseases. Like other R&D biopharmaceuticals, this chart shows operating losses per scientist. This reflects the cost of advanced research and clinical trials leading to the development of a new drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513929228 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Disc Medicine Inc. (IRON)
Disc Medicine is a biopharmaceutical company focused on treating hematological diseases. For a company in clinical development, this graph is a predictor of the future. It reflects the potential for successful drug development and commercialization to lead to significant revenue growth per employee.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Disc-Medicine-Inc.-IRON&v=1772513929255 "Sales chart per company employee Disc Medicine Inc. (IRON)")
Sales per employee in the market segment - Cancer blood
Disc Medicine is a clinical-stage biotech company focused on treating rare blood diseases. Revenue is not yet available. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies. It provides context for assessing the effectiveness of Disc Medicine's staff within the industry.
Sales per employee for the market as a whole
Disc Medicine is a clinical-stage biotechnology company specializing in the treatment of hematological diseases. The company has no commercial products and, consequently, no revenue from them. This metric is currently irrelevant. The R&D team is fully focused on successfully completing clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Disc Medicine Inc. (IRON)
Disc Medicine is a biotech company specializing in the treatment of rare blood diseases. Its key programs are in mid-stage clinical trials. This chart shows the volume of bets by "bears" who are skeptical of the scientific data underlying the company's drugs or fear failure in key phases of research.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Disc-Medicine-Inc.-IRON&v=1772513929518 "Short Shares Chart for the Company Disc Medicine Inc. (IRON)")
Shares shorted by market segment - Cancer blood
Disc Medicine, Inc. is a biopharmaceutical company focused on treating rare blood disorders (hematological diseases). They are working on modulating iron metabolism pathways. This chart shows the overall short position in the biotech sector. Its rise signals investor doubts about the clinical success or commercial potential of drugs for rare diseases in general.
Shares shorted by the overall market
Disc Medicine (IRON) is a clinical-stage biotech (hematology). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives IRON of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Disc Medicine Inc. (IRON)
Disc Medicine (IRON) is a biotech company developing new treatments for serious hematological (blood) diseases. Their stock is extremely sensitive to clinical trial news. This chart measures market hype. It shows when positive data pushes the price into overbought territory (above 70) or when delays push the price into oversold territory (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Disc-Medicine-Inc.-IRON&v=1772513929723 "RSI 14 indicator chart for the company's stock Disc Medicine Inc. (IRON)")
RSI 14 Market Segment - Cancer blood
Disc Medicine (IRON) is a biopharmaceutical company specializing in the treatment of hematological diseases (blood disorders), particularly those related to iron metabolism. This chart tracks overall sentiment in the Oncology/Hematology sector. It helps investors understand whether IRON's performance is reflective of its clinical data or whether the overall sector is overheated or oversold.
RSI 14 for the overall market
Disc Medicine (IRON) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IRON (Disc Medicine Inc.)
Ironwood Pharmaceuticals is a biopharmaceutical company specializing in the treatment of gastrointestinal (GI) diseases. Its flagship product is LINZESS, a treatment for IBS. This chart shows the average target price analysts are predicting based on LINZESS sales growth and new drug development.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IRON-Disc-Medicine-Inc.&v=1772513929754 "A chart showing analyst consensus forecasts for the expected stock price. IRON (Disc Medicine Inc.)")
The difference between the consensus estimate and the actual stock price IRON (Disc Medicine Inc.)
Disc Medicine (IRON) is a biotech company focused on treating rare blood disorders associated with iron metabolism. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their drug candidates for the treatment of anemia and other hematological diseases.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IRON-Disc-Medicine-Inc.&v=1772513929799 "A chart showing the difference between the consensus forecast and the actual stock price. IRON (Disc Medicine Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
Disc Medicine is a biotech company focused on treating serious hematological (blood) diseases, such as porphyria. This chart shows analysts' overall expectations for the blood oncology sector. It reflects whether experts believe new approaches to treating rare blood diseases are successful.
Analysts' consensus forecast for the overall market share price
Disc Medicine (IRON) is a clinical-stage biotech focused on treating blood disorders. It's a risky R&D play. This chart of overall market sentiment is important. Optimism = the market is willing to burn cash funding unprofitable biotechs with high potential. Pessimism = risk aversion, and capital for R&D dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Disc Medicine Inc.
Disc Medicine is a clinical-stage biotech company focused on developing novel treatments for hematological (blood) diseases, particularly those related to iron metabolism. This graph is an assessment of their scientific approach. Its dynamics depend entirely on their progress in clinical trials and the market's confidence in their R&D pipeline.
AKIMA Market Segment Index - Cancer blood
Disc Medicine (IRON) is a clinical-stage biotech focused on rare blood disorders (hematology); the company is developing new treatments for porphyria and anemia. This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark provides insight into how Disc's niche (rare blood) R&D focus differentiates it from the average pharma company.
The AKIM Index for the overall market
Disc Medicine is a biotech company developing treatments for serious hematological diseases (blood disorders). It's a high-risk scientific bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story, driven by trial news, compares to overall economic trends that influence risk appetite.
